Tvardi Therapeutics, Inc.
$3.22
▲
0.67%
2026-04-21 09:57:01
tvarditherapeutics.com
NCM: TVRD
Explore Tvardi Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$30.72 M
Current Price
$3.22
52W High / Low
$43.65 / $2.75
Stock P/E
—
Book Value
$2.23
Dividend Yield
—
ROCE
-127.18%
ROE
-2.38%
Face Value
—
EPS
$-3.26
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
12
Beta
—
Debt / Equity
0.96
Current Ratio
2.86
Quick Ratio
2.86
Forward P/E
-1.11
Price / Sales
—
Enterprise Value
$-3.4 M
EV / EBITDA
0.13
EV / Revenue
—
Rating
Buy
Target Price
$8.33
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 2. | Disc Medicine, Inc. | $71.41 | — | $2.74 B | — | -30.64% | -35.86% | $99.5 / $39.2 | $19.52 |
| 3. | Milestone Pharmaceuticals Inc. | $2.04 | — | $247.1 M | — | -62.4% | -2.3% | $3.06 / $0.77 | $0.34 |
| 4. | C4 Therapeutics, Inc. | $2.99 | — | $284.93 M | — | -32.05% | -44.44% | $3.82 / $1.09 | $2.65 |
| 5. | Phio Pharmaceuticals Corp. | $1.27 | — | $14.75 M | — | -45.76% | -69.95% | $4.19 / $0.81 | $1.73 |
| 6. | ProKidney Corp. | $2.1 | — | $634.02 M | — | -54.13% | -43.17% | $7.13 / $0.54 | $-7.13 |
| 7. | Instil Bio, Inc. | $8.39 | — | $56.9 M | — | -26.15% | -50.39% | $42.79 / $5.67 | $16.79 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 2.57 M | 0 M | — |
| Operating Profit | -7.59 M | -5.94 M | -8.87 M | -2.39 M | -10.8 M | — |
| Net Profit | -7.28 M | -5.53 M | 4.17 M | -4.91 M | -12.71 M | — |
| EPS in Rs | -0.78 | -0.59 | 0.44 | -0.52 | -1.35 | -0.59 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -26.75 M | -28.11 M | -18.66 M | -21.19 M |
| Net Profit | -18.21 M | -29.4 M | -17.35 M | -20.54 M |
| EPS in Rs | -1.94 | -3.13 | -1.85 | -2.19 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 32.07 M | 35.2 M | 27 M | 45.1 M |
| Total Liabilities | 11.13 M | 126.33 M | 89.06 M | 90.15 M |
| Equity | 20.95 M | -91.13 M | -62.06 M | -45.05 M |
| Current Assets | 31.54 M | 31.69 M | 26.16 M | 44.11 M |
| Current Liabilities | 11.04 M | 10.37 M | 3.28 M | 4.28 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.5 M | -18.3 M | -21.04 M | -17.87 M |
| Investing CF | -10.08 M | 0 M | 22.47 M | -22 M |
| Financing CF | 22.7 M | 27 M | 0 M | 0 M |
| Free CF | -23.5 M | -18.3 M | -21.04 M | -17.92 M |
| Capex | — | — | — | -0.05 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 38.04% | -69.46% | 15.55% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-04-16 | 1:0.333333 |
| 2024-12-31 | 1:0.0833333 |